OBJECTIVES: GCA patients with large vessel involvement (LV-GCA) experience greater CS requirements and higher relapse rates compared with classical cranial GCA. Despite the distinct disease course, interventions in LV-GCA have yet to be investigated specifically. This study aimed to evaluate the CS-sparing effect and tolerability of first-line mycophenolate in LV-GCA. METHODS: A retrospective cohort study was conducted in patients with LV-GCA identified from a regional clinical database between 2005 and 2019. All cases were prescribed mycophenolate derivatives (MYC; MMF or mycophenolic acid) at diagnosis and were followed up for ≥2 years. The primary outcome was the cumulative CS dose at 1 year. Secondary outcomes included MYC tolerance, relapse rates and CRP levels at 1 and 2 years. RESULTS: A total of 37 patients (65% female; mean age 69.4 years, SD 7.9 years) were identified. All cases demonstrated large vessel involvement via CT/PET (n = 34), CT angiography (n = 5) or magnetic resonance angiography (n = 2). After 2 years, 31 patients remained on MYC, whereas 6 had switched to MTX or tocilizumab owing to significant disease relapse. The mean (±SD) cumulative prednisolone dose at 1 year was 4960 (±1621) mg. Relapse rates at 1 and 2 years were 16.2 and 27%, respectively, and CRP levels at 1 and 2 years were 4 [interquartile range (IQR) 4-6] and 4 (IQR 4-4) mg/l, respectively. CONCLUSION: To our knowledge, this is the first attempt to assess the effectiveness of any specific agent in LV-GCA. MYC might be both effective in reducing CS exposure and well tolerated in this subpopulation. A future randomized controlled trial is warranted.
OBJECTIVES: GCA patients with large vessel involvement (LV-GCA) experience greater CS requirements and higher relapse rates compared with classical cranial GCA. Despite the distinct disease course, interventions in LV-GCA have yet to be investigated specifically. This study aimed to evaluate the CS-sparing effect and tolerability of first-line mycophenolate in LV-GCA. METHODS: A retrospective cohort study was conducted in patients with LV-GCA identified from a regional clinical database between 2005 and 2019. All cases were prescribed mycophenolate derivatives (MYC; MMF or mycophenolic acid) at diagnosis and were followed up for ≥2 years. The primary outcome was the cumulative CS dose at 1 year. Secondary outcomes included MYC tolerance, relapse rates and CRP levels at 1 and 2 years. RESULTS: A total of 37 patients (65% female; mean age 69.4 years, SD 7.9 years) were identified. All cases demonstrated large vessel involvement via CT/PET (n = 34), CT angiography (n = 5) or magnetic resonance angiography (n = 2). After 2 years, 31 patients remained on MYC, whereas 6 had switched to MTX or tocilizumab owing to significant disease relapse. The mean (±SD) cumulative prednisolone dose at 1 year was 4960 (±1621) mg. Relapse rates at 1 and 2 years were 16.2 and 27%, respectively, and CRP levels at 1 and 2 years were 4 [interquartile range (IQR) 4-6] and 4 (IQR 4-4) mg/l, respectively. CONCLUSION: To our knowledge, this is the first attempt to assess the effectiveness of any specific agent in LV-GCA. MYC might be both effective in reducing CS exposure and well tolerated in this subpopulation. A future randomized controlled trial is warranted.
Authors: Bernhard Hellmich; Ana Agueda; Sara Monti; Frank Buttgereit; Hubert de Boysson; Elisabeth Brouwer; Rebecca Cassie; Maria C Cid; Bhaskar Dasgupta; Christian Dejaco; Gulen Hatemi; Nicole Hollinger; Alfred Mahr; Susan P Mollan; Chetan Mukhtyar; Cristina Ponte; Carlo Salvarani; Rajappa Sivakumar; Xinping Tian; Gunnar Tomasson; Carl Turesson; Wolfgang Schmidt; Peter M Villiger; Richard Watts; Chris Young; Raashid Ahmed Luqmani Journal: Ann Rheum Dis Date: 2019-07-03 Impact factor: 19.103
Authors: Hubert de Boysson; Aurélie Daumas; Mathieu Vautier; Jean-Jacques Parienti; Eric Liozon; Marc Lambert; Maxime Samson; Mikael Ebbo; Anael Dumont; Audrey Sultan; Bernard Bonnotte; Alain Manrique; Boris Bienvenu; David Saadoun; Achille Aouba Journal: Autoimmun Rev Date: 2018-02-07 Impact factor: 9.754
Authors: Aladdin J Mohammad; Jan-Åke Nilsson; Lennart T H Jacobsson; Peter A Merkel; Carl Turesson Journal: Ann Rheum Dis Date: 2014-01-17 Impact factor: 19.103
Authors: Rachel B Jones; Thomas F Hiemstra; Jose Ballarin; Daniel Engelbert Blockmans; Paul Brogan; Annette Bruchfeld; Maria C Cid; Karen Dahlsveen; Janak de Zoysa; Georgína Espigol-Frigolé; Peter Lanyon; Chen Au Peh; Vladimir Tesar; Augusto Vaglio; Michael Walsh; Dorothy Walsh; Giles Walters; Lorraine Harper; David Jayne Journal: Ann Rheum Dis Date: 2019-01-05 Impact factor: 19.103
Authors: Tanaz A Kermani; Kenneth J Warrington; Cynthia S Crowson; Steven R Ytterberg; Gene G Hunder; Sherine E Gabriel; Eric L Matteson Journal: Ann Rheum Dis Date: 2012-12-19 Impact factor: 19.103
Authors: Alfred D Mahr; Juan A Jover; Robert F Spiera; César Hernández-García; Benjamin Fernández-Gutiérrez; Michael P Lavalley; Peter A Merkel Journal: Arthritis Rheum Date: 2007-08
Authors: Francesco Muratore; Tanaz A Kermani; Cynthia S Crowson; Abigail B Green; Carlo Salvarani; Eric L Matteson; Kenneth J Warrington Journal: Rheumatology (Oxford) Date: 2014-09-05 Impact factor: 7.580
Authors: John H Stone; Katie Tuckwell; Sophie Dimonaco; Micki Klearman; Martin Aringer; Daniel Blockmans; Elisabeth Brouwer; Maria C Cid; Bhaskar Dasgupta; Juergen Rech; Carlo Salvarani; Georg Schett; Hendrik Schulze-Koops; Robert Spiera; Sebastian H Unizony; Neil Collinson Journal: N Engl J Med Date: 2017-07-27 Impact factor: 91.245
Authors: Dan Pugh; Maira Karabayas; Neil Basu; Maria C Cid; Ruchika Goel; Carl S Goodyear; Peter C Grayson; Stephen P McAdoo; Justin C Mason; Catherine Owen; Cornelia M Weyand; Taryn Youngstein; Neeraj Dhaun Journal: Nat Rev Dis Primers Date: 2022-01-06 Impact factor: 65.038